User profiles for K.K. Wong

Kwok-Kin Wong

NYU Langone Health
Verified email at nyulangone.org
Cited by 71609

Non-small-cell lung cancers: a heterogeneous set of diseases

…, PS Hammerman, CF Kim, KK Wong - Nature Reviews …, 2014 - nature.com
Non-small-cell lung cancers (NSCLCs), the most common lung cancers, are known to have
diverse pathological features. During the past decade, in-depth analyses of lung cancer …

Multiplicity of beta-1, 4-xylanase in microorganisms: functions and applications

KK Wong, LU Tan, JN Saddler - Microbiological reviews, 1988 - Am Soc Microbiol
INTRODUCTION 3-1, 4-Xylans are heterogeneous polysaccharides found in the cell walls
of all land plants and in almost all plant parts (147). The hydrolysis of their characteristic …

Targeting the PI3K signaling pathway in cancer

KK Wong, JA Engelman, LC Cantley - Current opinion in genetics & …, 2010 - Elsevier
The phosphoinositide 3-kinase (PI3K) pathway is activated in a variety of different human
cancers, and inhibitors of this pathway are under active development as anti-cancer …

[HTML][HTML] A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

…, L Zou, MA Fischbach, KK Wong, K Brandstetter… - Cell, 2010 - cell.com
Accumulating evidence implicates heterogeneity within cancer cell populations in the response
to stressful exposures, including drug treatments. While modeling the acute response to …

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

…, MS Woo, H Greulich, KK Wong… - Proceedings of the …, 2008 - National Acad Sciences
… Steady-state initial velocity data were drawn from the slopes of the A 340 curves and fit to
the Michaelis-Menten equation to determine V m and K m values. To assure that our derived k

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

…, WJ Rettig, M Meyerson, F Solca, H Greulich, KK Wong - Oncogene, 2008 - nature.com
… Because HER3 has recently been identified as the mediator of activation of the PI3-K- … F
Solca, H Greulich and KK Wong: These laboratories contributed equally to this work. … KK Wong

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

…, R Weissleder, U Mahmood, LC Cantley, KK Wong - Nature medicine, 2008 - nature.com
Somatic mutations that activate phosphoinositide 3-kinase (PI3K) have been identified in the
p110-α catalytic subunit (encoded by PIK3CA) 1 . They are most frequently observed in two …

[HTML][HTML] Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

…, R Bueno, FS Hodi, G Dranoff, KK Wong… - Nature …, 2016 - nature.com
Despite compelling antitumour activity of antibodies targeting the programmed death 1 (PD-1):
programmed death ligand 1 (PD-L1) immune checkpoint in lung cancer, resistance to …

The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins

…, H Sun, MV Naniong, CJ Ott, CS Mitsiades, KK Wong… - Science, 2014 - science.org
Thalidomide-like drugs such as lenalidomide are clinically important treatments for multiple
myeloma and show promise for other B cell malignancies. The biochemical mechanisms …

High-throughput oncogene mutation profiling in human cancer

…, L Girard, K Majmudar, L Ziaugra, KK Wong… - Nature …, 2007 - nature.com
Systematic efforts are underway to decipher the genetic changes associated with tumor
initiation and progression 1 , 2 . However, widespread clinical application of this information is …